05/05/2026
In our recent paper, “Minimally invasive extracorporeal CO2 removal in hypercapnic respiratory failure: a prospective observational study," we show new advances in critical care.
Our study from the Gießen ARDS-ECMO Center highlights the potential of minimally invasive extracorporeal CO₂ removal (miECCO₂R) in patients with acute respiratory distress syndrome (ARDS).
Within just hours, this approach normalizes CO₂ levels in most patients with severe refractory hypercapnia and improves blood pH, subsequently enabling more lung-protective ventilation.
Why is this important? Both hypercapnia and ventilator-induced lung injury drive negative outcomes in patients with ARDS. Several previous studies addressed the role of conventional ECCO₂R in patients with respiratory failure to reduce ventilator pressures/volumes but showed negative results, mainly because of ECCO₂R-related side effects, such as bleeding events or hemolysis that might be in part an issue of technology, due to the use of centrifugal pumps.
Our ultra-low-flow method has several advantages. miECCO₂R uses a dialysis machine as a “motor”, a peristaltic pump that causes less hemolysis, and can be performed as standalone or in combination with renal replacement therapy, if needed, via a small dialysis catheter. Most importantly, in our cohort, no device-associated severe adverse events were observed, in particular, no major bleeding events occurred.
A promising step toward safer, less invasive and yet effective treatment strategies in intensive care – now awaiting further validation in larger clinical trials.
Find the full access paper here: https://link.springer.com/article/10.1186/s13054-026-06062-1.
